Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
|
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [31] Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer
    Kato, Yasuhiro
    Kashima, Jumpei
    Watanabe, Kageaki
    Yomota, Makiko
    Zenke, Yositaka
    Okuma, Yusuke
    Hosomi, Yukio
    Gemma, Akihiko
    Seike, Masahiro
    Okamura, Tatsuru
    ANTICANCER RESEARCH, 2018, 38 (02) : 1077 - 1083
  • [32] Heterogeneity of programmed cell death-ligand 1 expression in lung cancer
    Mansfield, Aaron
    Murphy, Stephen
    Peikert, Tobias
    Vasmatzis, George
    Wigle, Dennis
    Aubry, Marie Christine
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S31 - S32
  • [33] Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis
    Sahin, Songul
    Batur, Sebnem
    Aydin, Ovgu
    Ozturk, Tulin
    Turna, Akif
    Oz, Buge
    BALKAN MEDICAL JOURNAL, 2019, 36 (03) : 184 - 189
  • [34] Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
    Lantuejoul, Sylvie
    Damotte, Diane
    Hofman, Veronique
    Adam, Julien
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S89 - S101
  • [35] Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer
    Cui, Shaohua
    Su, Xinying
    Dong, Lili
    Qian, Jialin
    Ye, Lin
    Zhang, Tianwei
    Fu, Haihua
    Han, Hulin
    Huang, Jiaqi
    Yao, Yihong
    Gu, Yi
    Jiang, Liyan
    JOURNAL OF CANCER, 2017, 8 (19): : 4075 - 4082
  • [36] Harmonization of programmed cell death ligand-1 diagnostic assays in non-small cell lung cancer
    Popple, Amy
    Illidge, Timothy M.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S553 - S556
  • [37] Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines
    Yamane, Hiromichi
    Isozaki, Hideko
    Takeyama, Masami
    Ochi, Nobuaki
    Kudo, Kenichiro
    Honda, Yoshihiro
    Yamagishi, Tomoko
    Kubo, Toshio
    Kiura, Katsuyuki
    Takigawa, Nagio
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (04): : 1553 - 1557
  • [38] Correlation Between Pretreatment Neutrophil-toLymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
    Pirlog, Cristina-Florina
    Cotan, Horia Teodor
    Parosanu, Andreea
    Slavu, Cristina Orlov
    Popa, Ana Maria
    Iaciu, Cristian
    Olaru, Mihaela
    Oprita, Alexandru Vlad
    Nita, Irina
    Nitipir, Cornelia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [39] Immune-related adverse events as a predictor marker of response to programmed cell death 1/programmed death-ligand 1 axis inhibitors in patients with non-small cell lung cancer
    Charpidou, Andriani
    Patriarcheas, Vasilios
    Vathiotis, Ioannis
    Kokotou, Eleni
    Syrigos, Nikos
    Mani, Maria
    Stournara, Lamprini
    Gkiozos, Ioannis
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [40] Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy
    Ishii, Hidenobu
    Azuma, Koichi
    Kawahara, Akihiko
    Matsuo, Norikazu
    Tokito, Takaaki
    Kinoshita, Takashi
    Yamada, Kazuhiko
    Sasada, Tetsuro
    Akiba, Jun
    Hoshino, Tomoaki
    ONCOTARGET, 2017, 8 (37) : 61618 - 61625